Petros Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Petros Pharmaceuticals, Inc. (PTPI) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.30 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-06-30 was -$0.30.
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-03-31 was -$0.03.
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-09-30 was -$0.03.
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-06-30 was -$1.49.
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for fiscal 2025 was -$1.79.
- Petros Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was -$41.06.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.30 10-Q · filed 2026-08-13 | -$0.33 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.03 10-Q · filed 2026-05-13 | |||||
| 2025-12-31 | -$1.79 10-K · filed 2026-04-15 | |||||
| 2025-09-30 | -$0.03 10-Q · filed 2025-11-13 | -$2.23 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | -$1.49 10-Q · filed 2026-08-13 | -$1.58 10-Q · filed 2025-08-14 | -$3.55 10-Q · filed 2026-08-13 | -$3.73 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$8.46 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | -$41.06 10-K · filed 2026-04-15 | |||||
| 2024-09-30 | -$13.34 10-Q · filed 2025-11-13 | -$54.58 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | -$5.71 10-Q · filed 2025-08-14 | -$29.52 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$28.81 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |